Información del artículo
Resumen
La utilización habitual de etanercept en el tratamiento de la psoriasis conlleva que el dermatólogo se enfrente a situaciones en las que se cuestione la necesidad de la interrupción temporal del tratamiento. En este artículo se intentan establecer pautas sobre la interrupción de etanercept en determinadas circunstancias, como cirugías o vacunación, el tiempo de suspensión y el momento de la reintroducción del fármaco.
Palabras clave:
Etanercept
Cirugía
Vacunación
Interrupción
Abstract
The common use of etanercept in the treatment of psoriasis entails that the dermatologist may encounter situations in which the need for temporary interruption of treatment may arise. In this article, an attempt has been made to establish guidelines on the interruption of etanercept within some circumstances, such as surgeries or vaccinations, the suspension time and when to reintroduce the drug.
Keywords:
Etanercept
Surgery
Vaccination
Interruption
El Texto completo está disponible en PDF
Bibliografía
[1.]
Etanercept (Enbrel) [ficha técnica]. Thousand Oaks, CA: Immunex Corp; 2007.
[2.]
M. Lebwohl, J. Bagel, J.M. Gelfand, D. Gladman, K.B. Gordon, S. Hsu, et al.
From the Medical board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis.
J Am Acad Dermatol, 58 (2008), pp. 94-105
[3.]
Annexe III..
Gestion des principales situations particulières au cours d’un traitement par anti-TNF-α.
Ann Dermatol Venereol, 134 (2007), pp. 1008-1013
[4.]
P.J. Mease, C.T. Ritchlin, R.W. Martín, A.B. Gottlieb, S.W. Baumgartner, D.J. Burge, et al.
Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept.
J Rheumatol, 31 (2004), pp. 1356-1361
[5.]
M.C. Kapetanovic, T. Saxne, A. Sjoholm, L. Truedsson, G. Jönsson, P. Geborek.
Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis.
Rheumathology (Oxford), 45 (2006), pp. 106-111
[6.]
O. Elkayam, D. Caspi, T. Reitblatt, D. Charboneau, J.B. Rubins.
The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankilosing spondylitis.
Semin Arthritis Rheum, 33 (2004), pp. 283-288
[7.]
M.C. Kapetanovic, T. Saxne, J.A. Nilsson, P. Geborek.
Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients.
Rheumatology (Oxford), 46 (2007), pp. 608-611
[8.]
I. Fomin, D. Caspi, V. Levy, N. Varsano, Y. Shalev, D. Paran, et al.
Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers.
Ann Rheum Dis, 65 (2006), pp. 191-194
[9.]
T. Kubota, T. Nii, T. Nanki, H. Kohsaka, M. Harigai, Y. Komano, et al.
Anti-tumor necrosis factor therapy does not diminish the immune response to influenza vaccine in Japanese patients with arthritis rheumatoid.
Mod Rheumatol, 17 (2007), pp. 531-533
[10.]
V. Rodríguez-Valverde, R. Cáliz Cáliz, J.M. Álvaro-Gracia, J.L. MArenco, J. Mulero, J. Tornero, et al.
III Actualización del Consenso de la Sociedad Española de Reumatología sobre terapia biológica en la artritis reumatoide.
Reumatol Clin, 2 (2006), pp. S52-S59
[11.]
A. Ruyssen-Witrand, L. Gossec, C. Salliot, M. Luc, M. Duclos, S. Guignard, et al.
Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers.
Clin Exp Rheumatol, 25 (2007), pp. 430-436
[12.]
C. Bibbo, J.W. Goldberg.
Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy.
Foot Ankle Int, 25 (2004), pp. 331-335
[13.]
A.A. den Broeder, M.C. Creemers, J. Fransen, E. de Jong, D.J. de Rooij, A. Wymenga, et al.
Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study.
J Rheumatol, 34 (2007), pp. 689-695
[14.]
S. Corrao, G. Pistone, S. Arnone, L. Calvo, R. Scaglione, G. Licata.
Safety of etanercept therapy in rheumatoid patients undergoing surgery: preliminary report.
Clin Rheum, 26 (2007), pp. 1513-1515
[15.]
J.T. Giles, S.J. Bartlett, A.C. Gelber, S. Nanda, K. Fontaine, V. Ruffing, et al.
Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopaedic infection in rheumatoid arthritis.
Arthritis Rheum, 55 (2006), pp. 333-337
[16.]
Y. Bongartz.
Elective Orthopedic Surgery and Perioperative DMARD Management: Many Questions, Fewer Answers, and Some Opinions.
J Rheumatol, 34 (2007), pp. 653-655
[17.]
R. Koike, T. Takeuchi, K. Eguchi, N. Miyasaka.
Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis.
Mod Rheum, 17 (2007), pp. 451-458
[18.]
J. Ledingham, C. Deighton.
Update on the British Society of Rheumatology guidelines for prescribing TNF-alpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001).
Rheumatology, 44 (2005), pp. 157-163
Copyright © 2010. Academia Española de Dermatología y Venereología
